Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ASPI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsASP Isotopes recasts 2025 financials to reflect Skyline construction unit as discontinued
Filed July 16, 2026 · Period ending July 16, 2026 · ~1 min read
Key Changes
-
high
ASPI retrospectively recasts its 2025 10-K to present Skyline construction services business as discontinued operations following March 2026 deconsolidation, when the company retained only 8.6% ownership.
Item 8.01 verify on EDGAR → -
medium
Skyline discontinued operations generated $18.2M in sales for 2025, with $1.6M income to ASPI after allocating $15.9M to noncontrolling interests and recognizing a $17.4M fair value gain on investments.
Exhibit 99.1 view on EDGAR → -
high
ASPI completed acquisition of Renergen on January 6, 2026, issuing 14.3M shares to make Renergen (South Africa's leading onshore natural gas explorer and first integrated helium/LNG producer) a wholly owned subsidiary.
Exhibit 99.1 view on EDGAR → -
medium
ASPI acquired 60% of NuMed radiopharmacy for $0.8M on January 22, 2026, with option to purchase remaining 40% for $0.5M within two years, and invested $10M in Opeongo biotech on January 26, 2026.
Exhibit 99.1 view on EDGAR →
Summary
ASP Isotopes filed this 8-K to retrospectively recast its 2025 Form 10-K financial statements, presenting the Skyline construction services business as discontinued operations following the March 29, 2026 deconsolidation. The company retained only 8.6% of Skyline after the separation.
For 2025, Skyline contributed $1.6 million in income to ASPI after allocating $15.9 million to noncontrolling interests, with results now excluded from continuing operations and segment reporting. This is a presentation change, not a restatement, providing investors a clearer view of ASPI's core isotopes business going forward. The filing also discloses three significant transactions completed in early 2026.
ASPI acquired Renergen, South Africa's leading onshore natural gas explorer and first integrated helium/LNG producer, issuing 14.3 million shares on January 6, 2026 to make Renergen a wholly owned subsidiary. The company also acquired 60% of NuMed radiopharmacy for $0.8 million with an option for the remaining 40%, and invested $10 million in Opeongo biotech. These moves signal ASPI's strategic expansion beyond isotopes into adjacent energy and medical markets, though the Renergen share issuance represents material dilution for existing shareholders.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
We started presenting the construction services business as discontinued operations in our consolidated financial statements beginning with our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which was filed with the SEC on May 20, 2026. As previously disclosed, on March 29, 2026, we entered into the Securities Exchange Agreement and completed the deconsolidation of Skyline Builders Group Holding Limited (“Skyline”). We retained approximately 8.6% percent of the outstanding Class A ordinary and preferred shares of Skyline immediately following the deconsolidation.
ASP Isotopes filed this 8-K solely to retrospectively recast certain financial information from its 2025 Form 10-K to present the construction services business (Skyline) as discontinued operations. On March 29, 2026, the company completed the deconsolidation of Skyline and retained approximately 8.6% of Skyline's outstanding shares. The historical results of Skyline have been excluded from continuing operations and segment results for all periods presented. This is not an amendment or restatement of the 2025 Form 10-K, but a retrospective presentation change to align with the discontinued operations accounting treatment that became applicable when the separation was completed in March 2026.
Added in current filing · view on EDGAR →
Sales from external customers | $ 18,175 | Less: cost of sales | (16,397) | Gross profit | $ 1,778 | Selling, general and administrative expenses | (1,315) | Change in fair value of investments | 17,352 | Other expenses, net | (79) | Income from discontinued operations before income taxes | 17,736 | Income tax expense | (194)
Net loss before allocation to noncontrolling interests
17,542 | Less: Net income attributable to noncontrolling interests | 15,898 | Income from discontinued operations | $ 1,644
For the year ended December 31, 2025, Skyline's discontinued operations generated $18.2 million in sales with gross profit of $1.8 million. After SG&A expenses and a $17.4 million gain from change in fair value of investments, income from discontinued operations before tax was $17.7 million. After allocating $15.9 million to noncontrolling interests, ASP Isotopes recognized $1.6 million in income from discontinued operations. The substantial fair value gain reflects the investment revaluation following the deconsolidation transaction.
Added in current filing · view on EDGAR →
On January 6, 2026, the Company completed the acquisition of Renergen and acquired all of the issued Renergen Ordinary Shares from Renergen shareholders in exchange for shares of the Company's common stock at an exchange ratio of 0.09196 shares of Company common stock for each Renergen Ordinary Share (the “Consideration Shares”) through the implementation of the Scheme, resulting in the issuance of an aggregate of 14,270,000 Consideration Shares. As a result of the Transaction, Renergen became a direct, wholly owned subsidiary of ASP Isotopes.
ASP Isotopes completed the acquisition of Renergen on January 6, 2026, issuing 14,270,000 shares of common stock to Renergen shareholders at an exchange ratio of 0.09196 ASPI shares per Renergen share. Renergen became a wholly owned subsidiary and its shares were delisted from the Johannesburg Stock Exchange and Australian Securities Exchange. Renergen is South Africa's leading onshore natural gas explorer and the first integrated producer of both liquid helium and LNG from its Virginia Gas Project.
Added in current filing · view on EDGAR →
On January 22, 2026, the Company acquired 60% of the issued and outstanding membership interests of NuMed for $0.8 million. NuMed is an independent radiopharmacy dedicated to nuclear medicine and the science of radiopharmaceutical production. In addition to the purchase consideration, the Company has an option to purchase the remaining 40% of the issued and outstanding membership interests within two years following the closing for an agreed consideration totaling $0.5 million.
ASP Isotopes acquired 60% of NuMed, an independent radiopharmacy focused on nuclear medicine and radiopharmaceutical production, for $0.8 million on January 22, 2026, with an option to acquire the remaining 40% for $0.5 million within two years. Separately, on January 26, 2026, the company invested $10.0 million in Opeongo, Inc., a biotechnology company developing therapeutics using extracellular matrix modulation to target fibrosis, inflammation, and cancer, purchasing 4,356,918 shares of Series Seed-1 Preferred Stock at $2.2952 per share.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Company started presenting the construction services business as discontinued operations in our consolidated financial statements beginning with our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which was filed with the SEC on May 20, 2026. As previously disclosed, on March 29, 2026, the Company entered into the Securities Exchange Agreement and completed the deconsolidation of Skyline Builders Group Holding Limited ("Skyline"). The Company retained approximately 8.6% percent of the outstanding Class A ordinary and preferred shares of Skyline immediately following the deconsolidation.
ASPI is retrospectively recasting its 2025 Form 10-K financial statements to present the construction services business (Skyline Builders Group) as discontinued operations. This follows the March 29, 2026 deconsolidation of Skyline, after which ASPI retained only 8.6% ownership. The recast separates Skyline's historical results from continuing operations for all periods presented.
Added in current filing · verify on EDGAR →
This Form 8-K is being filed by us solely to retrospectively recast certain prior period financial information and related disclosures contained in the 2025 Form 10-K to present the operations of the construction services business as discontinued operations separately from our continuing operations. Included within Exhibit 99.1 to this Form 8-K and incorporated by reference herein are the following items of the 2025 Form 10-K, each recast to present the construction services business as discontinued operations in our consolidated financial information and certain related disclosures:
• Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations; and
• Part II, Item 8. Financial Statements and Supplementary Data.
The recast affects the MD&A and financial statements sections of the 2025 10-K. The company emphasizes this is not an amendment or restatement of the 10-K, but rather a retrospective presentation change to reflect discontinued operations accounting treatment for the construction services segment.
Added in current filing · verify on EDGAR →
The accounting requirements for reporting the separation of Skyline as a discontinued operation were met when the separation was completed. Accordingly, the historical results of Skyline have been presented as discontinued operations and, as such, have been excluded from continuing operations and segment results for all periods presented. Prior to the separation, Skyline was reported within the construction services segment.
Before the March 2026 deconsolidation, Skyline was reported as the construction services segment. Now that accounting requirements for discontinued operations treatment are met, all historical Skyline results are excluded from continuing operations and segment results, providing investors a clearer view of ASPI's ongoing isotopes business.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 17, 2026 · How we verify